Analyst Ratings
Here’s a summary of recent analyst ratings for Psykey and ResMed from MarketBeat.
| Sell | Hold | Buy | Strong Buy | Rating Score | |
| Psykey | 0 | 0 | 0 | 0 | N/A |
| ResMed | 1 | 5 | 6 | 1 | 2.54 |
ResMed’s target price is $218.18, indicating a potential drop of 9.09%. Analysts view ResMed more favorably than Psykey.
Insider & Institutional Ownership
55.0% of ResMed shares are held by institutions, while 1.2% are owned by insiders, showing strong belief in the company’s future performance.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Psykey | N/A | N/A | N/A | ($0.41) | -0.05 |
| ResMed | $4.69 billion | 7.53 | $1.02 billion | $6.51 | 36.87 |
ResMed outperforms Psykey in revenue and earnings. Psykey has a lower price-to-earnings ratio, making it cheaper.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Psykey | N/A | N/A | N/A |
| ResMed | 21.79% | 25.00% | 16.67% |
Summary
ResMed excels in every category compared to Psykey.
About Psykey
Psykey, Inc. researches and develops ingredients for health products, including functional mushroom drinks. Founded in 2002, it rebranded from CeCors in 2021 and is located in Toronto.
About ResMed
ResMed Inc. provides medical devices and software for sleep and respiratory care. Founded in 1989 and based in San Diego, it offers solutions for respiratory disorders, along with software for healthcare providers.
Receive Daily Updates on Psykey – Enter your email for the latest news and analyst ratings with MarketBeat.com’s FREE daily email newsletter.
`
